Business Context and Reporting Period
This Form 8-K is a current report filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) on March 21, 2016, regarding events occurring on March 17, 2016. The filing discloses the appointment of a new director and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes.
Material Changes
The primary material change is the appointment of Mr. Daniel M. Junius to the Board of Directors and the Audit Committee. Mr. Junius, currently the President and CEO of ImmunoGen, Inc., was appointed as a Class I director with a term expiring at the 2018 annual meeting of stockholders.
Compensation and Governance Details
- Stock Options: Mr. Junius was granted a nonqualified stock option to purchase 22,000 shares of common stock at an exercise price of $5.99 per share. The option vests in three equal installments over three years.
- Annual Retainer: He will receive a $35,000 annual retainer for board service and a $7,500 annual retainer for Audit Committee service.
- Future Grants: Upon each subsequent annual stockholder meeting where his term continues, he is entitled to an additional option for 11,000 shares vesting over one year.
- Indemnification: Mr. Junius has entered into the Company's standard indemnification agreement.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 22,000 share option grant.
- Confirm the total annual cash compensation ($42,500) for the new director.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Note that the filing explicitly states the press release is not "filed" for Section 18 liability purposes.